Taysha Gene Therapies, Inc. TSHA

Rank #2473 · Nasdaq · $1.2B market cap

Audited by Deloitte & Touche LLP, no going-concern flag in the latest filing.

Score

15.3

P/E

-13.3

P/B

15.84

ROE

-119.2%

Op. Margin

-1097.6%

Debt Ratio

119%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Poor

P/E -13.3x, P/B 15.84x. Ranks in the top 84% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -119.2%. Ranks in the top 96% of the universe.

Safety ★★★☆☆

Average

Debt ratio 119%. Ranks in the top 46% of the universe.

Growth ★☆☆☆☆

Poor

Revenue decline of 46.1% year over year. Ranks in the top 97% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2020	–	$-0.0B	$-0.1B	$0.0B	–	–
2021	–	$-0.0B	$-0.1B	$-0.0B	–	-5614
2022	$0.0B	$-0.2B	$-0.2B	$0.3B	-6925.1	47
2023	$0.0B	$-0.2B	$-0.2B	$0.1B	-6492.7	131
2024	$0.0B	$-0.1B	$-0.1B	$0.0B	-468.8	10305
2025	$0.0B	$-0.1B	$-0.1B	$0.1B	-1097.6	119